Alan’s €5B moment: can Europe’s health‑tech outlier succeed where US insurtech stumbled?

1. Headline & intro

Europe’s unicorn herd is shrinking, yet one animal is still sprinting. While many late‑stage startups are taking valuation cuts, French health insurance scale‑up Alan has just been marked up to €5 billion. That makes it not only a European outlier, but a live test of a hard question: can digital health insurance be both a high‑growth software story and a boringly solid, regulated insurer?

In this piece, we’ll look beyond the funding headline: why investors are doubling down now, what Alan’s numbers really signal, how this fits into the brutal history of insurtech, and what it means for Europe’s healthcare and tech ecosystem.

2. The news in brief

According to TechCrunch, French health insurance startup Alan has raised a new €100 million round led by existing backer Index Ventures, with participation from new investors Greenoaks, Kaaf and SH, plus business angels such as Shopify founder Tobi Lütke and footballer Antoine Griezmann. Strategic partner Belfius, the Belgian bank-insurer that led Alan’s previous Series F, also joined.

The round lifts Alan’s valuation to €5 billion, up from €4.5 billion in 2024. Founded in 2016, the company now employs around 740 people and serves about one million users (employees, freelancers and retirees) with health insurance and wellness services via its app.

As reported by TechCrunch, Alan claims €785 million in annual recurring revenue (ARR) for 2025, a 53% increase year‑on‑year, and says it is operationally profitable in France while approaching break‑even overall. The company has expanded from France into Belgium, Spain and, more recently, Canada, and is targeting roughly $1.16 billion in ARR in 2026, prioritising growth over full profitability.

3. Why this matters

Alan’s new valuation isn’t just another funding milestone; it’s a referendum on whether full‑stack insurtech still has a future after a painful global comedown.

Who benefits?

• Alan secures fresh capital to push harder into AI, product development and international markets without rushing to full profitability.
• Employers and workers get a stronger alternative to legacy insurers, with a consumer‑grade app experience layered on top of often archaic healthcare systems.
• European tech gets a rare, credible late‑stage success story in a segment (regulated financial services) where many investors have become skittish.

Who loses?

• Traditional insurers and mutuals in France, Belgium and Spain now face a capitalised competitor that is no longer a small startup rounding error.
• Younger insurtechs may find investors comparing every deck to Alan’s metrics – a harsher bar in a funding market that already favours perceived winners.

Crucially, Alan is not chasing growth at all costs. The company claims operating profitability in its core French market and narrowed losses relative to revenue globally, while still growing ARR above 50%. That blend – high growth plus a visible path to sustainable margins – is precisely what public investors punished US insurtechs for lacking.

By explicitly choosing to aim for $1.16 billion ARR in 2026 instead of immediate global profitability, Alan is making a calculated bet: that in a highly regulated, capital‑intensive space, land‑grab and product breadth still matter more than short‑term earnings, as long as unit economics are under control.

If that thesis proves right, Alan could become the reference model for the next wave of European fintech and healthtech scale‑ups.

4. The bigger picture

To understand why Alan’s €5B mark‑up is notable, you have to look at the wreckage in its category.

US peers like Oscar Health, Clover and Lemonade showed how hard it is to be simultaneously a tech company, an underwriter and a growth stock. Aggressive customer acquisition, optimistic risk models and the reality of medical inflation collided; public market valuations fell sharply compared with their peak. In the UK, Babylon Health went from unicorn to insolvency, a warning about over‑promising AI‑driven healthcare.

Alan is explicitly trying to write a different story on three fronts:

1. Full‑stack from day one. Alan obtained its own insurance licence in France, rather than acting as a slick frontend reselling someone else’s product. That brings heavier regulation and capital requirements, but also control over pricing, risk and product design.
2. Insurance plus services. Its app bundles reimbursements, telemedicine access and wellness tools. That broadens the value proposition beyond “a cheaper policy” and creates daily or weekly touchpoints, not just yearly renewals or claim events.
3. AI as infrastructure, not marketing. The CEO’s visible proximity to Mistral AI matters: if Alan can use AI credibly for claims automation, risk scoring, fraud detection and personalised care pathways – while staying on the right side of regulators – its cost structure and customer experience could diverge significantly from incumbents.

This also fits a wider shift across fintech: the winners are increasingly those that combine regulated balance sheets (banks, insurers) with strong software DNA, rather than light‑touch apps sitting on top of someone else’s licence. Think Solaris and bunq in banking, or wefox and Ottonova in insurance. Alan is the health‑insurance expression of that trend.

5. The European / regional angle

Health insurance in Europe is a very different game than in the US – and Alan’s trajectory reflects that.

Most EU countries have universal or near‑universal public coverage. The commercial opportunity is in supplementary insurance (better hospital rooms, dental, optical, faster access) and in helping employers manage increasingly complex benefit packages across borders.

Alan’s win of a French civil‑service contract covering up to 135,000 people, as reported by TechCrunch, is emblematic. This isn’t about replacing the state; it’s about wrapping fragmented public entitlements, employer top‑ups and private options into a single, understandable experience.

Regulation will heavily shape how far Alan can go:

• GDPR forces strict handling of highly sensitive health data; any AI‑enabled profiling must pass tough legal and ethical tests.
• The EU AI Act classifies many healthcare‑related AI systems as “high‑risk”, imposing documentation, transparency and oversight obligations. If Alan leans into AI triage, decision support or automated underwriting, compliance costs will be non‑trivial.
• Under Solvency II, expanding across the EU is easier via passporting, but still demands significant capital buffers and risk governance – a natural moat against smaller copycats.

For European employers running teams across France, Spain, Benelux and eventually DACH or the Nordics, a pan‑European, digital‑first health partner is attractive. That is the slice of the market Alan is clearly positioning for. Whether it can crack more complex markets like Germany or Italy will be the next big test.

6. Looking ahead

The next 24–36 months will determine whether Alan is on a path to become Europe’s default digital health insurer or stalls as a strong but regional player.

Things to watch:

1. Execution in Canada. Moving beyond Europe removes the comfort of EU passporting and forces adaptation to new regulatory regimes. Canada is a good proving ground before any push into the US or other large markets.
2. Move into high‑value EU markets. Germany, the Netherlands and the Nordics have affluent, digital-savvy populations but complex insurance frameworks. A German launch, if it comes, would signal real ambition.
3. Depth of AI integration. Announcing AI ambitions is easy; using AI safely on real medical and claims data is hard. Expect regulators to scrutinise Alan’s models, especially if they influence coverage decisions or care pathways.
4. Path to IPO. With nearly $1 billion ARR in sight and losses shrinking relative to revenue, Alan is moving into the revenue range where public markets become realistic. A 2028–2030 IPO window, likely with a strong Euronext component, is a plausible scenario if markets stay open.

Risks are clear: claims volatility, political backlash if Alan is seen as a vehicle for stealth privatisation, integration challenges in new countries, and the ever‑present danger of overpaying for growth. But there is also upside: if Alan can prove that a tech‑centric insurer can scale responsibly in Europe, it may unlock investor appetite for the next generation of regulated fintechs.

7. The bottom line

Alan’s €5B valuation is not a return to 2021‑style hype; it is a significant, but conditional, vote of confidence in a business that mixes high growth with increasingly disciplined economics. If it executes, Alan could become the flagship example of how to modernise Europe’s healthcare financing without importing the worst of US‑style insurance. The open question for readers – especially employers and policymakers – is whether they are ready to let digital players sit closer to the core of their healthcare systems.